No reports of adverse events related to the recall have been reported
TUESDAY, Nov. 3, 2020 (HealthDay News) — A cancer-causing compound in the drug metformin has resulted in the recall of two lots of the drug.
Kansas City-based Nostrum Laboratories Inc., said Monday that it is voluntarily recalling its metformin HCl extended release tablets, USP 750 mg, according to a notice from the U.S. Food and Drug Administration. No reports of adverse events related to the recall have been reported, the company said.
These tablets are tainted with higher-than-safe levels of the chemical nitrosamine, or NDMA. NDMA is a possible carcinogen, according to the U.S. Environmental Protection Agency.
The affected product is packaged in HDPE bottles of 100 tablets, under NDC 29033-056-01. The affected Metformin HCl Extended Release Tablets, USP 750 mg lots are under NDC 29033-056-01, lot numbers MET200101 and MET200301, with the expiration date 05/2022. It can be identified as an off-white oblong tablet debossed with “NM7.”
Genetics, Diabetes Tied to MASLD-Associated Cirrhosis Before Age 50 
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors 
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus .jpg)
Recommendations Updated for Management of Anemia in CKD 
More Advanced CKM Syndrome Linked to Worse Cardiovascular Health 
Preoperative IV Iron Beneficial for Patients With Anemia Undergoing Cardiac Surgery 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
2011 to 2021 Saw Heart Failure-Related Hospitalization Rise in CKD 
.jpg)
